Davis Polk advised Lazard as financial adviser to Adamas Pharmaceuticals on the deal while Saul Ewing Arnstein & Lehr represented Supernus. Adamas Pharmaceuticals announced its $450 million...
This content is for Standard 1 Year members only. LoginJoin Now